Shares of Iambic Therapeutics closed at $18.91 on Thursday in their Nasdaq debut, up about 18 percent from the $16 IPO price, after the Nvidia-backed AI drugmaker raised $150 million in a listing that priced at the midpoint of its marketed range.
The San Diego-based company sold about 9.38 million shares at $16 each late Wednesday, October 14, giving it a market value of roughly $896 million based on outstanding shares. The Iambic IPO shares opened at $16.15 on Thursday and at one stage traded near $19 before settling at $18.91 — an 18.2 percent first-day gain.
The Iambic IPO was led by JPMorgan, Jefferies, BofA Securities and Citigroup as joint bookrunners, and the shares trade on the Nasdaq Global Select Market under the ticker IAM.
Inside the Iambic IPO pricing
Iambic had marketed the shares at $15 to $17, and the midpoint pricing signaled solid institutional demand. ARK Investment Management, an existing shareholder, and Stanley Druckenmiller’s Duquesne Family Office had indicated interest in buying up to $60 million combined at the offering price, according to the prospectus. That insider demand helped steady the Iambic IPO amid a crowded biotech calendar.
The company describes itself as a clinical-stage life sciences and technology company advancing novel medicines with an AI-driven platform, and it counts Nvidia as a shareholder — the chipmaker invested $25 million across two preferred rounds, its filing shows. Iambic has raised about $461.8 million from technology and healthcare investors since its 2019 founding. The offering includes a 30-day option for underwriters to buy up to about 1.4 million additional shares at the IPO price, and the company expects roughly $135 million in net proceeds. Mid-afternoon volume reached about 1.61 million shares as the stock traded above $19.
For the six months ended June 30, 2026, Iambic reported a net loss of $50.1 million on revenue of $12.8 million, versus a net loss of $33.2 million on revenue of $3.9 million a year earlier. The company estimates its cash plus offering proceeds will last into or through the fourth quarter of 2028.
What the Iambic IPO money will fund
Iambic said it will use the proceeds to advance three early-stage cancer drug candidates and discover new treatments, including potential therapies for breast and ovarian cancer and intracranial tumors. Its lead asset, IAM1363, is an oral tyrosine kinase inhibitor in a Phase 1/1b trial for advanced HER2-altered solid tumors, with a potentially registrational study expected to begin next year.
The company has also been building pharma partnerships: a September collaboration with AbbVie to accelerate AI-enabled drug discovery in immunology, neuroscience and oncology, and a June drug-discovery collaboration with Bayer focused on small molecules. Its prospectus lists additional partnerships with Takeda, Lundbeck, Lambda, Jazz Pharmaceuticals and Revolution Medicines.
Every dollar of Iambic’s first-half revenue came from collaboration money — upfront fees, research services and a single milestone payment — and every program remains in Phase 1 or earlier. The Iambic IPO is thus a bet less on near-term product revenue than on the platform’s ability to compress drug-discovery timelines.
Why the Iambic IPO tests AI biotech hype
Skeptics of the Iambic IPO note the gap between the AI branding and the budget: in the first half of 2026, the cloud computing that trains Iambic’s flagship Enchant model cost $4.4 million, while running human trials on lead drug IAM1363 cost $17.4 million. On both the cost and revenue sides, the business looks much like a young clinical-stage biotech with a machine-learning operation attached.
Still, the debut’s pop suggests public-market appetite for AI-infused biotech remains strong, and a clean first day could encourage other AI-focused drug startups to list. Over the next 12 months, clinical data — starting with IAM1363 — will determine whether the Iambic IPO’s promise of faster, cheaper drug discovery survives contact with trial results. Investors will be watching IAM1363’s Phase 1/1b readouts first.